Incyte Announces First Patient Treated in ECHO-301 Phase 3 Study
Go back to Incyte Announces First Patient Treated in ECHO-301 Phase 3 Study| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 128.47 +5.00 (4.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $123.47 | 52 Week High | $118.49 | |||
| Open | $125.00 | 52 Week Low | $55.00 | |||
| Day High | $129.56 | P/E | N/A | |||
| Day Low | $124.60 | EPS | $-0.56 | |||
| Volume | 1,588,976 | |||||
